AstraZeneca Plc has struck deals with companies operating in China and Japan giving it access to novel compounds in the therapeutic areas of oncology and diabetes. The separate deals involve preclinical and clinical assets. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
